These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594 [TBL] [Abstract][Full Text] [Related]
3. Severe tumefactive rebound of multiple sclerosis following fingolimod cessation. Salam S; Mihalova T; Siripurapu R BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27261513 [No Abstract] [Full Text] [Related]
4. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. Berger B; Baumgartner A; Rauer S; Mader I; Luetzen N; Farenkopf U; Stich O J Neuroimmunol; 2015 May; 282():118-22. PubMed ID: 25903738 [TBL] [Abstract][Full Text] [Related]
5. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes. Gulec B; Everest E; Gorkey OD; Koc M; Tutuncu M; Saip S; Siva A; Uygunoglu U Eur J Neurol; 2023 Sep; 30(9):2745-2751. PubMed ID: 37300847 [TBL] [Abstract][Full Text] [Related]
6. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis. Meinl I; Havla J; Hohlfeld R; Kümpfel T Mult Scler; 2018 Jun; 24(7):991-994. PubMed ID: 28920764 [TBL] [Abstract][Full Text] [Related]
7. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R; CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with fingolimod rebound: A single center real-life experience. Goncuoglu C; Tuncer A; Bayraktar-Ekincioglu A; Ayvacioglu Cagan C; Acar-Ozen P; Cakan M; Karabulut E; Karabudak R Mult Scler Relat Disord; 2021 Nov; 56():103278. PubMed ID: 34655957 [TBL] [Abstract][Full Text] [Related]
9. A case of early disease rebound after fingolimod discontinuation in a patient with multiple sclerosis and SARS-CoV-2 infection. Giovannini B; Panelli D; Bianchi F; Siciliano G; Pasquali L Neurol Sci; 2024 Jun; 45(6):2423-2426. PubMed ID: 38546935 [TBL] [Abstract][Full Text] [Related]
11. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis. Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365 [TBL] [Abstract][Full Text] [Related]
13. What happens after fingolimod discontinuation? A multicentre real-life experience. Landi D; Signori A; Cellerino M; Fenu G; Nicoletti CG; Ponzano M; Mancuso E; Fronza M; Ricchiuto ME; Boffa G; Inglese M; Marfia GA; Cocco E; Frau J J Neurol; 2022 Feb; 269(2):796-804. PubMed ID: 34136943 [TBL] [Abstract][Full Text] [Related]
14. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series. Delgado S; Hernandez J; Tornes L; Rammohan K BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945 [TBL] [Abstract][Full Text] [Related]
15. Recurring disease activity in relapsing remitting multiple sclerosis: The multicenter RDA-RMS study. Tunç A; Yetkin MF; Seferoğlu M; İnanç Y; Sıvacı AÖ; Türkoğlu ŞA; Baydar C; Güzel V; Bülbül NG; Sezer V; Altun Y Mult Scler Relat Disord; 2024 Aug; 88():105757. PubMed ID: 38972107 [TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498 [TBL] [Abstract][Full Text] [Related]
17. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study. Maunula A; Atula S; Laakso SM; Tienari PJ Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790 [TBL] [Abstract][Full Text] [Related]
18. Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports. Zanetta C; Filippi M; Moiola L Neurol Sci; 2021 May; 42(Suppl 1):9-13. PubMed ID: 33904006 [TBL] [Abstract][Full Text] [Related]